REGISTRATION PREPARATIONS FULLY UNDERWAY
FIRST QUARTER (JAN-
- EBITDA
SEK -5.4 million (-3.6) * -
Operating profit (EBIT)
SEK -6.1 million (-4.2) * -
Profit after tax
SEK -5.0 million (-3.4) * -
Total profit
SEK 18.6 million (-3.4) -
Diluted earnings per share
SEK 0.46 (-0.18) * -
Cash and cash equivalents amounted to
SEK 133.6 million (51.6) -
Cash and cash equivalents
SEK 142 million adjusted for effects ofOncoZenge divestment (reversed in Q2)
* All comparative figures refer to continuing operations
SIGNIFICANT EVENTS IN THE FIRST QUARTER
- A patent was granted for MOB-015 in
India , adding to previously granted patents in major markets such as theU.S. ,Canada , the EU,China andJapan . Patent term until 2032. Moberg Pharma's rights issue ofSEK 150 million was carried out and registered. The rights issue was approved by the Extraordinary General Meeting inDecember 2020 and was fully subscribed without issue guarantees.-
The Lex Asea distribution of
OncoZenge shares was completed. Ten ordinary shares inMoberg Pharma entitled one share inOncoZenge AB .OncoZenge was listed withFebruary 12 as the first day of trading on Nasdaq First North Growth Market. OncoZenge was granted a new European patent for BUPI. The new patent provides broad protection for sustained-release lozenges containing bupivacaine, for treatment or alleviation of pain in the oral cavity, and is based on a previously granted patent providing protection for pain treatment of oral mucositis in cancer patients.
SIGNIFICANT EVENTS AFTER THE FIRST QUARTER
- On
April 19, 2021 , the Nomination Committee proposed Nikolaj Sörensen, President and CEO ofOrexo , as a new member of the Board of Directors.
STATEMENT FROM THE CEO
Registration preparations for MOB-015 are progressing at full speed, including recently received final comments on our pediatric plan from EMA, compilation of a single safety database with data from all MOB-015 studies and development of the product label in collaboration with our partners. We remain on plan to submit the registration application in
Preparations for registration in
Regarding intellectual property rights, we were recently granted a patent in
In February, BUPI was spun off via a distribution of shares in
Altogether, I am very pleased with the team and progress made in the quarter. It is a significant commitment for a small company to get a new medication to market approval in multiple markets, and it is gratifying to see how the pieces are getting into place for the EU submission. Based on two completed phase 3 studies, MOB-015 has significant opportunity to create value at limited risk, which over time will provide increasing awareness of the potential within
CONFERENCE CALL -
CEO
Dial in: SE: +46 8 566 427 03, US: +1 833 823 05 86
ABOUT THIS INFORMATION
This information is information that
FOR ADDITIONAL INFORMATION
https://news.cision.com/moberg-pharma/r/moberg-pharma-ab-interim-report-january---march-2021,c3344326
https://mb.cision.com/Main/1662/3344326/1415556.pdf
(c) 2021 Cision. All rights reserved., source